BioWorld

Oct. 22, 2003

Vertex, GSK Receive Approval For Flexible HIV Drug Lexiva

Vertex Pharmaceuticals Inc. and partner GlaxoSmithKline plc won FDA approval of Lexiva, an HIV protease inhibitor that can be dosed once or twice daily, with or without food and water restrictions. (BioWorld Today) Read More

Cypress Bioscience Begins Milnacipran Phase III Trial

Cephalon's Provigil Receives Approval For Expanded Label

Biospect Raises $27M In Series A Round; Diagnostics First Focus

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2026.

CINP 2026: Prenatal and adolescent stress shape brain vulnerability

BioWorld Science

Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...

Ontrack Therapeutics divulges compounds for neurodegenerative diseases

BioWorld Science

Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.

AI-generated image for brain organoid neural research

CINP 2026: organoids reveal autism and addiction mechanisms

BioWorld Science

At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...

Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists

BioWorld Science

Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...